Stocks
NeoGenomics Projects $797M-$803M 2026 Revenue
NeoGenomics forecasts significant revenue growth for 2026, projecting between $797 million and $803 million, boosted by the PanTracer Liquid MolDX approval.
NeoGenomics forecasts significant revenue growth for 2026, projecting between $797 million and $803 million, boosted by the PanTracer Liquid MolDX approval.